Explore 3 Stock Ideas & Industry Insights Download Free Report

News

AutoNation (NYSE:AN): Record After-Sales Profit Against Softer New-Vehicle Volumes

AutoNation (NYSE:AN) rose 1.41% to $204.08 at last closing. One of the largest U.S. automotive retailers grew its adjustedEarningsfor a sixth consecutive quarter, with a record after-sales gross profit and a scaling captive-finance business, even as new-vehicle volumes softened. For investors, the question is …

Nitish Kishor | 02 September 2026

US Sector Performance: Energy Leads While Consumer Discretionary and Technology Lag

The latest US sector performance data for 1 September 2026 shows a mixed but predominantly weak market environment, with Energy (XLE) standing out after gaining 1.27%. Utilities (XLU), Health Care (XLV) and Consumer Staples (XLP) also advanced, while seven sectors declined.

Robert Luong | 01 September 2026

US Sector Momentum Analysis: Energy Leads While Technology Moves into Weakening

The latest US sector momentum visualization for 1 September 2026 continues to show a rotational structure, with four sectors positioned in Leading, four in Improving, one in Weakening and two in Lagging. Energy, Health Care, Materials and Communication Services remain in the Leading quadrant, …

Robert Luong | 01 September 2026

This NASDAQ Biotech Is Nearing a 52-Week High Today: Here's Why

Vir Biotechnology (NASDAQ:VIR) shares are trading higher, nearing their 52-week high, as investors continue to build on the momentum from strong second-quarter results, which showedEarnings Per Shareof $0.47 against a $0.33 consensus estimate, with revenue up sharply year over year.

Nitish Kishor | 01 September 2026

Why Is This NYSE Healthcare Stock Falling Today Amid a Bizarre Weekend Trading Glitch?

Hims & Hers Health (NYSE:HIMS) shares are trading lower, giving back Monday's gain tied to news of the company's Australia expansion, as broader market weakness tied to surging oil prices, a U.S.-Iran conflict escalation, and rising Treasury yields pressures risk assets across sectors.

Nitish Kishor | 01 September 2026

Kailera Therapeutics (NASDAQ:KLRA) Rebounds 10% After Tumbling to a 52-Week Low

Kailera Therapeutics (NASDAQ:KLRA) shares are rebounding sharply after tumbling to a fresh 52-week low in the prior session, when the stock fell more than 12% and traded barely above its April IPO price, pressuring its marketCapitalizationto roughly its cash balance. The bounce comes amid …

Nitish Kishor | 01 September 2026

MiniMed Group (NASDAQ:MMED) Trades Up 11% to a Fresh 52-Week High on Strong Q1 Results

MiniMed Group (NASDAQ:MMED) shares surged to a fresh 52-week high after the insulin delivery company reported fiscal Q1 2027 results that topped internal expectations, with net sales of $843 million, up 15.8% organically, driven by strong growth in pumps and continuous glucose monitors. The …

Nitish Kishor | 01 September 2026

Encouraging Oncology Data Sends Moderna (NASDAQ:MRNA) Up 10%

Moderna (NASDAQ:MRNA) shares are surging as investor enthusiasm builds around the company's oncology pipeline. The move follows late-August Phase 3 data showing that intensimeran autogene, Moderna's personalized cancer vaccine developed with Merck (NYSE:MRK), significantly reduced melanoma recurrence and metastasis risk when combined with Merck's …

Nitish Kishor | 01 September 2026

Novartis (NYSE:NVS) Rises 6% Despite a Safety Update on CAR-T Therapy Studies

Novartis (NYSE:NVS) shares rose sharply after the company announced that its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product. The results mark the first success …

Nitish Kishor | 01 September 2026

Novavax (NASDAQ:NVAX) Shares Rise 9% on Updated Vaccine Emergency Use Authorization

Novavax (NASDAQ:NVAX) shares are surging as investors respond to the company's late-August FDA emergency use authorization for its updated 2026-2027 protein-based Nuvaxovid COVID-19 vaccine formula, positioning the company as a non-mRNA alternative for the upcoming fall vaccination season.

Nitish Kishor | 01 September 2026
Support

Hi! How can we help you today?

Loading…